ValuEngine Lowers Evolent Health, Inc (EVH) to Sell
ValuEngine downgraded shares of Evolent Health, Inc (NYSE:EVH) from a hold rating to a sell rating in a research report report published on Friday.
EVH has been the subject of a number of other reports. Jefferies Group LLC reiterated a buy rating and set a $28.00 price target on shares of Evolent Health in a report on Thursday, April 13th. Zacks Investment Research downgraded shares of Evolent Health from a buy rating to a hold rating in a report on Thursday, May 4th. Robert W. Baird initiated coverage on shares of Evolent Health in a report on Thursday, June 1st. They set an outperform rating and a $30.00 price target for the company. Leerink Swann reiterated an outperform rating and set a $32.00 price target (up from $30.00) on shares of Evolent Health in a report on Monday, June 19th. Finally, Cowen and Company reiterated an outperform rating and set a $35.00 price target on shares of Evolent Health in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Evolent Health has an average rating of Buy and a consensus price target of $29.73.
Evolent Health (NYSE EVH) opened at 24.70 on Friday. The firm’s market capitalization is $1.43 billion. Evolent Health has a 12-month low of $14.50 and a 12-month high of $27.50. The firm has a 50-day moving average of $25.80 and a 200 day moving average of $22.58.
Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, May 9th. The technology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The business had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $104.38 million. During the same quarter last year, the business posted ($0.16) earnings per share. The business’s revenue was up 116.2% compared to the same quarter last year. On average, equities analysts predict that Evolent Health will post ($0.41) EPS for the current year.
In related news, COO Thomas Peterson III sold 40,540 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $26.00, for a total value of $1,054,040.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Cheryl Scott sold 5,477 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $23.51, for a total transaction of $128,764.27. The disclosure for this sale can be found here. Insiders sold 10,183,238 shares of company stock worth $254,360,928 over the last three months. Corporate insiders own 8.79% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. US Bancorp DE boosted its stake in Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares in the last quarter. Point72 Asia Hong Kong Ltd bought a new stake in Evolent Health during the first quarter valued at about $126,000. Bank of Montreal Can boosted its stake in Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after buying an additional 6,077 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Evolent Health by 286.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,744 shares of the technology company’s stock valued at $150,000 after buying an additional 5,000 shares in the last quarter. Finally, IPG Investment Advisors LLC bought a new stake in Evolent Health during the first quarter valued at about $206,000. 73.47% of the stock is currently owned by institutional investors and hedge funds.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.